Skip to NavigationSkip to content

Dr Eliot Forster to lead MedCity

Published on: 08/04/14

Dr Eliot Forster has been appointed chairman of MedCity Limited by the London mayor Boris Johnson.

Dr Forster has 20 years of industry experience in biotechnology and pharmaceutical companies. He was most recently the chief executive of Solace Pharmaceuticals, a US-based biotech, before becoming chief executive of European biotech Creabilis.

Prior joining Solace, Dr Forster was Head of EU development and of development operations in the EU & Asia at Pfizer.

During his career at Pfizer Dr Forster was integral to bringing a number of drugs to market, including Celebrex (celecoxib) and Bextra (valcecoxib).

He holds a PhD from Liverpool University and an MBA from Henley Management College.

He has held a number of non-executive director roles in the biotech sector and has been an advisor to the UKTI Life Sciences Strategy Board.

Speaking at the launchof MedCity Dr Forster said: “This is a singular opportunity for this sector to find its rightful place in the world market; to create new companies, new therapies, new investments and to deliver economic and patient benefits.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches